Date: 2015-02-02
Type of information: Nomination
Compound:
Company: Symbiosis Pharmaceutical Services (UK)
Therapeutic area: Technology - Services
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 2, 2015, Symbiosis Pharmaceutical Services has further strengthened its North American presence with the appointment of another experienced U.S. based business development executive. The CMO has engaged Rich Masino to promote its commercial interests on the West Coast of the U.S., which follows the recent appointment of business development manager Derek Richards to oversee its commercial interests on the East Coast.
With over 25 years’ experience in the biotech, life science, and pharmaceutical sectors, Rich Masino has specialised in the pharmaceutical contract manufacturing sector over the last decade. Prior to that he has held product development positions at Molecular Devices and Affymetrix and senior commercial roles at Stratagene (Agilent Technologies) and LIFE Technologies (ThermoFisher). He joins Symbiosis to support the CMO’s strategic focus by promoting its core aseptic manufacturing services in North America. Growing demand for these services has been fuelled by increased demand for small scale biologic and small molecule sterile production capabilities to support a growing number of clinical trials globally.
Symbiosis specialises in sterile injectables and the aseptic manufacturing of drug products into vials. Its core manufacturing capability takes place within a purpose-built facility in Stirling, Scotland, designed for the manufacture and quick release of sterile drug products at clinical and niche market scale.
Financial terms:
Latest news:
